Anti-obesity drugs and neural circuits of feeding.
Most of the drugs that have entered the market for treating obesity were originally developed to treat psychiatric diseases. During the past decade, understanding of the neural circuits that underlie food intake has increased considerably. Different aspects of ingestive behavior such as meal termination, meal initiation and overconsumption of highly rewarding and palatable foods are modulated by different neuroanatomical structures. Integration of the action of many signaling molecules (e.g. hormones, neurotransmitters and neuropeptides) in these structures results in a response that, ultimately, modulates food intake. Thus, the type of drug required by an obese patient might depend on the individual cause of obesity. In this article, we summarize the neural circuits that regulate food intake and we provide a framework for understanding how obesity drugs function. Several potential drug targets are expressed in different neural circuits, implying that current and future obesity drugs act on partially overlapping systems that control food intake.
Adan
Roger A H
RA
Rudolf Magnus Institute of Neuroscience, Department of Neuroscience and Pharmacology, UMC Utrecht, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands. r.a.h.adan@umcutrecht.nl <r.a.h.adan@umcutrecht.nl>
Vanderschuren
Louk J M J
LJ
la Fleur
Susanne E
SE
D000818:Animals; D019440:Anti-Obesity Agents / Q000494:pharmacology*; D001111:Arcuate Nucleus of Hypothalamus / Q000502:physiology; D001921:Brain / Q000502:physiology*; D006801:Humans; D009638:Norepinephrine / Q000502:physiology; D009714:Nucleus Accumbens / Q000502:physiology; D009765:Obesity / Q000503:physiopathology*; D019894:Peptide YY / Q000502:physiology; D011333:Pro-Opiomelanocortin / Q000502:physiology; D012527:Satiation; D012701:Serotonin / Q000502:physiology
D019440:Anti-Obesity Agents; D019894:Peptide YY; D012701:Serotonin; D011333:Pro-Opiomelanocortin; D009638:Norepinephrine